PerkinElmer, Inc. (NYSE:PKI) insider Andrew Okun sold 2,324 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $75.44, for a total transaction of $175,322.56. Following the completion of the sale, the insider now owns 8,876 shares of the company’s stock, valued at $669,605.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Andrew Okun also recently made the following trade(s):
- On Monday, February 5th, Andrew Okun sold 2,273 shares of PerkinElmer stock. The shares were sold at an average price of $77.86, for a total transaction of $176,975.78.
- On Friday, December 15th, Andrew Okun sold 12,680 shares of PerkinElmer stock. The shares were sold at an average price of $72.00, for a total transaction of $912,960.00.
PerkinElmer, Inc. (PKI) traded up $0.77 on Friday, reaching $72.83. 1,212,966 shares of the company’s stock traded hands, compared to its average volume of 769,324. The company has a current ratio of 1.27, a quick ratio of 0.90 and a debt-to-equity ratio of 0.72. PerkinElmer, Inc. has a 12 month low of $53.63 and a 12 month high of $84.49. The stock has a market capitalization of $8,351.76, a P/E ratio of 25.95, a P/E/G ratio of 1.75 and a beta of 0.76.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 10th. Shareholders of record on Friday, April 13th will be paid a dividend of $0.07 per share. The ex-dividend date is Thursday, April 12th. This represents a $0.28 annualized dividend and a yield of 0.38%. PerkinElmer’s dividend payout ratio is currently 10.61%.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cutler Group LP lifted its position in shares of PerkinElmer by 845.7% during the fourth quarter. Cutler Group LP now owns 2,237 shares of the medical research company’s stock worth $163,000 after purchasing an additional 2,537 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its position in shares of PerkinElmer by 53.8% during the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,228 shares of the medical research company’s stock worth $170,000 after purchasing an additional 779 shares in the last quarter. Waldron LP acquired a new position in shares of PerkinElmer during the third quarter worth $200,000. Seaward Management Limited Partnership acquired a new position in shares of PerkinElmer during the third quarter worth $202,000. Finally, Signition LP acquired a new position in shares of PerkinElmer during the fourth quarter worth $207,000. Institutional investors own 90.98% of the company’s stock.
A number of equities research analysts recently issued reports on PKI shares. Bank of America upgraded shares of PerkinElmer from an “underperform” rating to a “neutral” rating and set a $78.00 target price for the company in a report on Tuesday, December 19th. Robert W. Baird boosted their target price on shares of PerkinElmer from $75.00 to $78.00 and gave the company an “outperform” rating in a report on Friday, November 3rd. Zacks Investment Research upgraded shares of PerkinElmer from a “hold” rating to a “buy” rating and set a $86.00 target price for the company in a report on Monday, January 8th. Evercore ISI started coverage on shares of PerkinElmer in a report on Wednesday, January 3rd. They issued an “in-line” rating and a $77.00 target price for the company. Finally, Jefferies Group restated a “hold” rating and issued a $70.00 target price on shares of PerkinElmer in a report on Friday, October 20th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $76.85.
PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.